These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 9349421)

  • 1. Immunoregulation of intraocular tumours.
    Niederkorn JY
    Eye (Lond); 1997; 11 ( Pt 2)():249-54. PubMed ID: 9349421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The immunopathology of intraocular tumour rejection.
    Niederkorn JY
    Eye (Lond); 1991; 5 ( Pt 2)():186-92. PubMed ID: 2070879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppressed cellular immunity in mice harboring intraocular melanomas.
    Niederkorn JY
    Invest Ophthalmol Vis Sci; 1984 Apr; 25(4):447-54. PubMed ID: 6608506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between natural killer cell susceptibility and metastasis of human uveal melanoma cells in a murine model.
    Ma D; Luyten GP; Luider TM; Niederkorn JY
    Invest Ophthalmol Vis Sci; 1995 Feb; 36(2):435-41. PubMed ID: 7843912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Destructive and nondestructive patterns of immune rejection of syngeneic intraocular tumors.
    Knisely TL; Luckenbach MW; Fischer BJ; Niederkorn JY
    J Immunol; 1987 Jun; 138(12):4515-23. PubMed ID: 3108394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alloantigens placed into the anterior chamber of the eye induce specific suppression of delayed-type hypersensitivity but normal cytotoxic T lymphocyte and helper T lymphocyte responses.
    Niederkorn JY; Streilein JW
    J Immunol; 1983 Dec; 131(6):2670-4. PubMed ID: 6196396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In situ suppression of delayed-type hypersensitivity: another mechanism for sustaining the immune privilege of the anterior chamber.
    Benson JL; Niederkorn JY
    Immunology; 1991 Sep; 74(1):153-9. PubMed ID: 1937568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spontaneous immune rejection of intraocular tumors in mice.
    Niederkorn JY; Meunier PC
    Invest Ophthalmol Vis Sci; 1985 Jun; 26(6):877-84. PubMed ID: 3924853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of tumor-infiltrating lymphocytes in the treatment of hepatic metastases arising from transgenic intraocular tumors in mice.
    Ma D; Niederkorn JY
    Invest Ophthalmol Vis Sci; 1995 May; 36(6):1067-75. PubMed ID: 7730016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour-associated macrophages and melanoma tumourigenesis: integrating the complexity.
    Hussein MR
    Int J Exp Pathol; 2006 Jun; 87(3):163-76. PubMed ID: 16709225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Termination of systemic immunity in the presence of intraocular tumors: influence of ocular immune privilege on tumor vaccines.
    Chen PW; Ksander BR
    Curr Eye Res; 2006 Jan; 31(1):43-55. PubMed ID: 16421019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early-appearing tumour-infiltrating natural killer cells play a crucial role in the generation of anti-tumour T lymphocytes.
    Kurosawa S; Harada M; Matsuzaki G; Shinomiya Y; Terao H; Kobayashi N; Nomoto K
    Immunology; 1995 Jun; 85(2):338-46. PubMed ID: 7642226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efferent blockade of delayed-type hypersensitivity responses in the anterior chamber of the eye.
    Niederkorn JY; Benson JL; Mayhew E
    Reg Immunol; 1990-1991; 3(6):349-54. PubMed ID: 2132760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunosuppressive activity of cloned natural killer (NK1.1+) T cells established from murine tumor-infiltrating lymphocytes.
    Tamada K; Harada M; Abe K; Li T; Tada H; Onoe Y; Nomoto K
    J Immunol; 1997 May; 158(10):4846-54. PubMed ID: 9144500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour-infiltrating lymphocytes and melanoma tumorigenesis: an insight.
    Hussein MR
    Br J Dermatol; 2005 Jul; 153(1):18-21. PubMed ID: 16029321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular mechanisms of lymphocyte-mediated lysis of tumor cells.
    Arancia G; Malorni W; Donelli G
    Ann Ist Super Sanita; 1990; 26(3-4):369-84. PubMed ID: 2151107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
    Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
    Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo.
    Prévost-Blondel A; Zimmermann C; Stemmer C; Kulmburg P; Rosenthal FM; Pircher H
    J Immunol; 1998 Sep; 161(5):2187-94. PubMed ID: 9725210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Demonstration of intratumoral infiltration of tumor-specific Lyt-1+2- T cells mediating delayed-type hypersensitivity response and in vivo protective immunity.
    Tomita S; Fujiwara H; Yamane Y; Sano S; Nakajima H; Izumi Y; Arai H; Kawanishi Y; Tsuchida T; Hamaoka T
    Jpn J Cancer Res; 1986 Feb; 77(2):182-9. PubMed ID: 3082830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy.
    Liu S; Etto T; Rodríguez-Cruz T; Li Y; Wu C; Fulbright OJ; Hwu P; Radvanyi L; Lizée G
    J Immunother; 2010 May; 33(4):371-81. PubMed ID: 20386469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.